or
forgot password

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment


Phase 1/Phase 2
19 Years
70 Years
Not Enrolling
Both
Breast Cancer

Thank you

Trial Information

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment


Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous
Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin
for Stage IV Breast Cancer & Limited Prior Treatment


Inclusion Criteria:

- stage IV breast cancer

- primary breast cancer does not express CD34+

- adequate organ function

- no evidence of active infection

Exclusion Criteria:- chemotherapy within 4 weeks

- CNS disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Feasibility and safety

Outcome Time Frame:

unknown

Safety Issue:

Yes

Principal Investigator

Ginna Laport

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BMT86

NCT ID:

NCT00186680

Start Date:

September 1996

Completion Date:

June 2005

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317